234 related articles for article (PubMed ID: 38130721)
21. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
Shen C; Chai W; Han J; Zhang Z; Liu X; Yang S; Wang Y; Wang D; Wan F; Fan Z; Hu H
Front Immunol; 2023; 14():1213947. PubMed ID: 37965307
[TBL] [Abstract][Full Text] [Related]
22. Eph receptor B6 shapes a cold immune microenvironment, inhibiting anti-cancer immunity and immunotherapy response in bladder cancer.
Jia X; Zhang D; Zhou C; Yan Z; Jiang Z; Xie L; Jiang J
Front Oncol; 2023; 13():1175183. PubMed ID: 37637034
[TBL] [Abstract][Full Text] [Related]
23. Apoptosis related genes mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide immunotherapy in bladder cancer.
Zhou L; Xu G; Huang F; Chen W; Zhang J; Tang Y
BMC Med Genomics; 2023 Apr; 16(1):88. PubMed ID: 37118734
[TBL] [Abstract][Full Text] [Related]
24. Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile.
Peng M
Front Immunol; 2022; 13():970885. PubMed ID: 36003383
[TBL] [Abstract][Full Text] [Related]
25. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
[TBL] [Abstract][Full Text] [Related]
26. Hypoxia is correlated with the tumor immune microenvironment: Potential application of immunotherapy in bladder cancer.
Chen H; Zhang Y; Chen X; Xu R; Zhu Y; He D; Cheng Y; Wang Z; Qing X; Cao K
Cancer Med; 2023 Dec; 12(24):22333-22353. PubMed ID: 38063246
[TBL] [Abstract][Full Text] [Related]
27. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and immunotherapy response in bladder cancer.
Shi X; Dong A; Yang Y; Zheng G; Wang N; Yang C; Wang Y; Lu J; Jia X
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9733-9746. PubMed ID: 37244876
[TBL] [Abstract][Full Text] [Related]
28. A risk model based on pyroptosis subtypes predicts tumor immune microenvironment and guides chemotherapy and immunotherapy in bladder cancer.
Wu T; Li S; Yu C; Wu Y; Long H
Sci Rep; 2022 Dec; 12(1):21467. PubMed ID: 36509838
[TBL] [Abstract][Full Text] [Related]
29. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
Zhao S; Wang L; Ding W; Ye B; Cheng C; Shao J; Liu J; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1180404. PubMed ID: 37152941
[TBL] [Abstract][Full Text] [Related]
30. A comprehensive analysis of immunogenic cell death and its key gene HSP90AA1 in bladder cancer.
Song Q; Zhou Z; Bai J; Liu N
Clin Transl Oncol; 2023 Aug; 25(8):2587-2606. PubMed ID: 37000291
[TBL] [Abstract][Full Text] [Related]
31. Functional status analysis of RNH1 in bladder cancer for predicting immunotherapy response.
Chen S; Ran J; Fan Z; Liu M; Wu L; Li Q; Peng J; Hu Z
Sci Rep; 2023 Aug; 13(1):12625. PubMed ID: 37537337
[TBL] [Abstract][Full Text] [Related]
32. Identification of molecular subtypes based on liquid-liquid phase separation and cross-talk with immunological phenotype in bladder cancer.
Sun L; Liu XP; Yan X; Wu S; Tang X; Chen C; Li G; Hu H; Wang D; Li S
Front Immunol; 2022; 13():1059568. PubMed ID: 36518754
[TBL] [Abstract][Full Text] [Related]
33. Interferon-Induced Transmembrane Protein 3 Shapes an Inflamed Tumor Microenvironment and Identifies Immuno-Hot Tumors.
Cai Y; Ji W; Sun C; Xu R; Chen X; Deng Y; Pan J; Yang J; Zhu H; Mei J
Front Immunol; 2021; 12():704965. PubMed ID: 34456915
[TBL] [Abstract][Full Text] [Related]
34. Cuproptosis scoring system to predict the clinical outcome and immune response in bladder cancer.
Song Q; Zhou R; Shu F; Fu W
Front Immunol; 2022; 13():958368. PubMed ID: 35990642
[TBL] [Abstract][Full Text] [Related]
35. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
[TBL] [Abstract][Full Text] [Related]
36. 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer.
Hu J; Othmane B; Yu A; Li H; Cai Z; Chen X; Ren W; Chen J; Zu X
BMC Med; 2021 Nov; 19(1):289. PubMed ID: 34836536
[TBL] [Abstract][Full Text] [Related]
37. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
Pan G; Xie H; Xia Y
Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive analysis of CXCL12 expression reveals the significance of inflammatory fibroblasts in bladder cancer carcinogenesis and progression.
Du Y; Cao J; Jiang X; Cai X; Wang B; Wang Y; Wang X; Xue B
Cancer Cell Int; 2021 Nov; 21(1):613. PubMed ID: 34801033
[TBL] [Abstract][Full Text] [Related]
39. The G protein-coupled receptor-related gene signatures for predicting prognosis and immunotherapy response in bladder urothelial carcinoma.
Wan Z; Wang Y; Li C; Zheng D
Open Life Sci; 2023; 18(1):20220682. PubMed ID: 37588995
[TBL] [Abstract][Full Text] [Related]
40. FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer.
Xu PH; Chen S; Wang Y; Jin S; Wang J; Ye D; Zhu X; Shen Y
Comput Biol Med; 2023 Aug; 162():106976. PubMed ID: 37301098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
